Korean J Helicobacter  Up Gastrointest Res Search


Korean J Helicobacter  Up Gastrointest Res > Volume 12(4); 2012 > Article
The Korean Journal of Helicobacter  and Upper Gastrointestinal Research 2012;12(4):219-223.
DOI: https://doi.org/10.7704/kjhugr.2012.12.4.219    Published online December 10, 2012.
Recent Trends of Helicobacter pylori Eradication Therapy in Korea
Yun Kyeong Kim, Joon Sung Kim, Byung Wook Kim
Division of Gastroenterology, Incheon St. Mary's Hospital, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Incheon, Korea. gastro@catholic.ac.kr
헬리코박터 제균 치료의 현재와 미래-국내의 제균 치료 현황
김윤경, 김준성, 김병욱
가톨릭대학교 의과대학 내과학교실 인천성모병원 소화기내과
Helicobacter pylori infection is one of the most common gastrointestinal infectious diseases in Korea and is related to diseases such as gastritis, peptic ulcer disease, marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, and gastric adenocarcinoma. The eradication of H. pylori infection requires combinations of antibiotics and acid suppressants. Triple therapy has been considered as the first-line therapy for a long time. However, its eradication rate is declining and we need more effective strategies. Quadruple therapy including acid suppressants, bismuth, and other two antibiotics is a main rescue therapy after first-line therapy failure in Korea. In this review, we describe new therapeutic regimens and new trends of H. pylori eradication in Korea.
Key Words: Helicobacter pylori; Eradication

Editorial Office
Lotte Gold Rose II Room 917, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-717-5543    Fax: +82-2-565-9947    E-mail: helicojournal@smileml.com                

Copyright © 2024 by Korean College of Helicobacter and Upper Gastrointestinal Research.

Developed in M2PI

Close layer
prev next